This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hu, Z. Articles by Gao, Y. Search for Related Content PubMed PubMed Citation Articles by Hu, Z. Articles by Gao, Y. Related Collections Clinical Research Clinical Research: Imaging, Diagnosis, and Prognosis

Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non–Small Cell Lung Cancer

Authors' Affiliations: Departments of ¹ Etiology and Carcinogenesis and ² Pathology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, and ³ Department of Thoracic Surgery, Liaoning Cancer Hospital, Shenyang, P.R. China

Requests for reprints: Yanning Gao, Department of Etiology and Carcinogenesis, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, 17 Panjiayuan Nanli, Beijing 100021, P.R. China. Phone: 86-10-6778-2323; Fax: 86-10-6776-7548; E-mail: yngao{at}pubem.cicams.ac.cn.

Purpose: The extracellular matrix (ECM) molecule osteopontin is implicated in many pathologic processes, including inflammation, cell proliferation, ECM invasion, tumor progression, and metastasis. The present study evaluated the clinical and biological importance of osteopontin in human lung cancer.

Experimental Design and Results: Tissue microarrays derived from non–small cell lung cancer (NSCLC) patients were analyzed immunohistochemically. Osteopontin protein expression was observed in 64.5% (205 of 318) of primary tumors and 75.5% (108 of 143) of lymph node metastases, but in only 27.9% (12 of 43) of normal-appearing bronchial epithelial and pulmonary tissues. Osteopontin expression was associated with tumor growth, tumor staging, and lymph node invasion. In vitro osteopontin enhanced ECM invasion of NSCLC cells, and an osteopontin antibody abolished this effect. We further analyzed osteopontin levels in circulating plasma derived from 158 patients with NSCLC, 54 patients of benign pulmonary disease, and 25 healthy donors, and found that the median osteopontin levels for the three groups were 319.1, 161.6, and 17.9 ng/mL, respectively.

Conclusions: Overexpression of osteopontin is common in primary NSCLC and may be important in the development and progression of the cancer. Osteopontin levels in the plasma may serve as a biomarker for diagnosing or monitoring patients with NSCLC.

This article has been cited by other articles:

				G. Huang, Z. Hu, M. Li, Y. Cui, Y. Li, L. Guo, W. Jiang, and S. H. Lu ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity Carcinogenesis, November 1, 2007; 28(11): 2274 - 2281. [Abstract] [Full Text] [PDF]

				B.-D. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, M. Gregoire, H. Porte, M.-C. Copin, and P. Lassalle Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment Clin. Cancer Res., May 15, 2007; 13(10): 2928 - 2935. [Abstract] [Full Text] [PDF]

				L. Packer, S. Pavey, A. Parker, M. Stark, P. Johansson, B. Clarke, P. Pollock, M. Ringner, and N. Hayward Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN Carcinogenesis, September 1, 2006; 27(9): 1778 - 1786. [Abstract] [Full Text] [PDF]

				Q.-T. Le, E. Chen, A. Salim, H. Cao, C. S. Kong, R. Whyte, J. Donington, W. Cannon, H. Wakelee, R. Tibshirani, et al. An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non-Small Cell Lung Cancers Clin. Cancer Res., March 1, 2006; 12(5): 1507 - 1514. [Abstract] [Full Text] [PDF]

				A. C. Khodavirdi, Z. Song, S. Yang, C. Zhong, S. Wang, H. Wu, C. Pritchard, P. S. Nelson, and P. Roy-Burman Increased Expression of Osteopontin Contributes to the Progression of Prostate Cancer Cancer Res., January 15, 2006; 66(2): 883 - 888. [Abstract] [Full Text] [PDF]